AMN · Amn Healthcare Services Inc
$34.50
+0.01 (+0.03%)
At close · Aug 14
Market Cap
$1.34B
Shares
38.73M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$34.50
Open$34.50
Day$34.21–34.96
52W close$15.10–36.60
Avg vol 30d834K
Short int3.4M · 8.8% float · 5.4d
Short vol62%
Last earningsAug 6, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 7
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 7, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+50%
above
Price vs 50-day avg
+5%
above
RSI (14)
53
neutral
MACD trend
Negative
52-week position
90%
near high
Momentum
relative strength
1-month return
−1%
trailing
6-month return
+66%
trailing
YTD return
+119%
this year
Relative strength
+52%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $33 › 200d $23 — 50d above 200d
Institutional flow
Accumulating
+13% holders QoQ · +77 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
8.78% of float · ▼ -6.0% MoM · 5.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
283 holders — mid 3-yr range
Squeeze score
67
elevated · 0–100
Fundamentals
Revenue growth
+5%
Y/Y
Gross margin
39%
contracting
EPS growth
+36%
Y/Y
Free cash flow
$233.8M
Valuation
P/E 12.8
below peers
Buyback
$226.7M
remaining
Balance sheet
$114.7M
net debt
Quant / Vol
risk profile
Volatility
68%
annualized · 1-yr
Max drawdown
−29%
past year
ATR
6.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Dec 31, 2025
Organic revenue growth
· after 2026
4% – 6%
Adjusted EBITDA growth
· after 2026
10% – 15%
Prior guidance
period ended
· from the Earnings Call filed Mar 31, 2026
Nurse and Allied Solutions revenue
· second quarter
-2% – 0%
Physician and Leadership Solutions revenue
· second quarter
-8% – -6%
Technology and Workforce Solutions revenue
· second quarter
-16% – -14%
Guided vs delivered
· last 1 settled
Consolidated revenue
fourth quarter of 2025
guided $715M – $730M
$748.23M
Beat +3.6%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+50%
Bullish
Price vs 50-day avg
+5%
Bullish
RSI (14)
53
Neutral
MACD trend
Negative
Bearish
52-week position
90%
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $33 › 200d $23 — 50d above 200d
Institutional flow
Accumulating
+13% holders QoQ · +77 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
8.78% of float · ▼ -6.0% MoM · 5.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
283 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $15
Now $35 · 90%
Range high $37
vs 200-day avg +50%
vs 50-day avg +5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AMN
this stock
Amn Healthcare Services Inc
|
$1.34B | +118.9% | +4.5% | 12.8 | 8.8% |
|
HCA
HCA Healthcare, Inc.
|
$89.77B | -13.3% | +7.1% | 13.9 | 2.7% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$30.87B | -4.4% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$21.57B | +34.8% | +0.9% | 10.3 | 4.0% |
|
FMS
Fresenius Medical Care AG
|
$12.65B | -0.2% | +5.9% | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AMN | -4.2% | -1.4% | +65.8% | +2.6% | +118.9% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -4.6% | -5.9% | +52.0% | -1.3% | +105.1% |
Capital returns
Buyback program
· as of Mar 31, 2026
Authorized
$1.35B
Spent (derived)
$1.12B
Remaining
$226.70M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
1142750
CUSIP
001744101
13F (30d)
272 filings
267 filers
Visit website
Investor relations